Page last updated: 2024-10-24

carbazilquinone and Dysmyelopoietic Syndromes

carbazilquinone has been researched along with Dysmyelopoietic Syndromes in 1 studies

Carbazilquinone: An alkylating agent structurally similar to MITOMYCIN and found to be effective in the treatment of leukemia and various other neoplasms in mice. It causes leukemia and thrombocytopenia in almost all human patients.

Research Excerpts

ExcerptRelevanceReference
"A 77-year-old male, who had been treated with carboquone and busulfan for polycythemia vera (PV), developed myelodysplastic syndrome (MDS) 8 years later."3.68[Polycythemia vera terminating in myelodysplastic syndrome]. ( Abe, T; Kimura, S; Kobayashi, Y; Kondo, M; Maruo, N; Ozawa, M; Tanaka, R; Uoshima, N; Yoshida, Y, 1990)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kimura, S1
Uoshima, N1
Tanaka, R1
Kobayashi, Y1
Ozawa, M1
Maruo, N1
Kondo, M1
Abe, T1
Yoshida, Y1

Other Studies

1 other study available for carbazilquinone and Dysmyelopoietic Syndromes

ArticleYear
[Polycythemia vera terminating in myelodysplastic syndrome].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1990, Volume: 31, Issue:1

    Topics: Aged; Busulfan; Carbazilquinone; Humans; Male; Myelodysplastic Syndromes; Polycythemia Vera

1990